Document is current

Article History

Received: 17 January 2022

Accepted: 22 March 2022

First Online: 15 April 2022

Declarations

:

: PROFILE samples were selected and sequenced from patients who were consented under institutional review board (IRB)-approved protocol 11-104 and 17-000 from the Dana-Farber/Partners Cancer Care Office for the Protection of Research Subjects. Written informed consent was obtained from participants or their guardian prior to inclusion in this study. Secondary analyses of previously collected data were performed with approval from the Dana-Farber IRB (DFCI IRB protocol 18-439 and 19-025; waiver of HIPAA authorization approved for both protocols). The research conformed to the principles of the Helsinki Declaration.

: Not applicable.

: Pasi A. Jänne reports support from Hanmi Pharmaceutical Company, Ltd; grants from Boehringer-Ingelheim, Eli Lilly, Daiichi Sankyo, and Takeda Oncolog; personal fees from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Ignyta, Loxo Oncology, Eli Lilly, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Sanofi Oncology, Takeda Oncology, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax, Astellas, PUMA, and Revolution Medicines, outside the submitted work; and postmarketing royalties from a Dana-Farber Cancer Center–owned patent (EGFR Mutations) licensed to Lab Corp.Lynette M. Sholl reports consulting fees from EMD Serono, Foghorn Therapeutics, and AstraZeneca and research grants from Genentech.Mark M. Awad reports receiving grants and personal fees from Genentech, AstraZeneca, and Bristol-Myers Squibb; grants from Eli Lilly; and personal fees from Merck, Maverick, Blueprint Medicine, Syndax, Ariad, Nektar, and Gritstone, outside of the submitted work. David J. Kwiatkowski reports receiving grants from Genentech, Revolution Medicines, and AADI; and consulting fees from Guidepoint and BridgeBio Gene Therapy.The remaining authors declare that they have no competing interests.